CD30

CD30, also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker.

This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. It is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.cite web | title = Entrez Gene: TNFRSF8 tumor necrosis factor receptor superfamily, member 8| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=943| accessdate = ]

CD30 is associated with anaplastic large cell lymphoma. It is expressed in embryonal carcinoma but not in seminoma and is thus is a useful marker in distinguishing between these germ cell tumors. [cite journal |author=Teng LH, Lu DH, Xu QZ, Fu YJ, Yang H, He ZL |title= [Expression and diagnostic significance of OCT4, CD117 and CD30 in germ cell tumors] |language=Chinese |journal=Zhonghua Bing Li Xue Za Zhi |volume=34 |issue=11 |pages=711–5 |year=2005 |pmid=16536313 |doi=]

References

Further reading

PBB_Further_reading
citations =
*cite journal | author=Schneider C, Hübinger G |title=Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family. |journal=Leuk. Lymphoma |volume=43 |issue= 7 |pages= 1355–66 |year= 2003 |pmid= 12389614 |doi=
*cite journal | author=Horie R, Higashihara M, Watanabe T |title=Hodgkin's lymphoma and CD30 signal transduction. |journal=Int. J. Hematol. |volume=77 |issue= 1 |pages= 37–47 |year= 2003 |pmid= 12568298 |doi=
*cite journal | author=Tarkowski M |title=Expression and a role of CD30 in regulation of T-cell activity. |journal=Curr. Opin. Hematol. |volume=10 |issue= 4 |pages= 267–71 |year= 2004 |pmid= 12799531 |doi=
*cite journal | author=Granados S, Hwang ST |title=Roles for CD30 in the biology and treatment of CD30 lymphoproliferative diseases. |journal=J. Invest. Dermatol. |volume=122 |issue= 6 |pages= 1345–7 |year= 2004 |pmid= 15175022 |doi= 10.1111/j.0022-202X.2004.22616.x
*cite journal | author=Dürkop H, Latza U, Hummel M, "et al." |title=Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. |journal=Cell |volume=68 |issue= 3 |pages= 421–7 |year= 1992 |pmid= 1310894 |doi=
*cite journal | author=Fonatsch C, Latza U, Dürkop H, "et al." |title=Assignment of the human CD30 (Ki-1) gene to 1p36. |journal=Genomics |volume=14 |issue= 3 |pages= 825–6 |year= 1992 |pmid= 1330892 |doi=
*cite journal | author=Josimovic-Alasevic O, Dürkop H, Schwarting R, "et al." |title=Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells "in vitro" and "in vivo". I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. |journal=Eur. J. Immunol. |volume=19 |issue= 1 |pages= 157–62 |year= 1989 |pmid= 2537734 |doi=
*cite journal | author=Stein H, Gerdes J, Schwab U, "et al." |title=Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population. |journal=Int. J. Cancer |volume=30 |issue= 4 |pages= 445–59 |year= 1983 |pmid= 6754630 |doi=
*cite journal | author=Jung W, Krueger S, Renner C, "et al." |title=Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources. |journal=Mol. Immunol. |volume=31 |issue= 17 |pages= 1329–34 |year= 1995 |pmid= 7527901 |doi=
*cite journal | author=Shiota M, Fujimoto J, Semba T, "et al." |title=Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. |journal=Oncogene |volume=9 |issue= 6 |pages= 1567–74 |year= 1994 |pmid= 8183550 |doi=
*cite journal | author=Lee SY, Park CG, Choi Y |title=T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors. |journal=J. Exp. Med. |volume=183 |issue= 2 |pages= 669–74 |year= 1996 |pmid= 8627180 |doi=
*cite journal | author=Gedrich RW, Gilfillan MC, Duckett CS, "et al." |title=CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. |journal=J. Biol. Chem. |volume=271 |issue= 22 |pages= 12852–8 |year= 1996 |pmid= 8662842 |doi=
*cite journal | author=Horie R, Ito K, Tatewaki M, "et al." |title=A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages. |journal=Blood |volume=88 |issue= 7 |pages= 2422–32 |year= 1996 |pmid= 8839832 |doi=
*cite journal | author=Ansieau S, Scheffrahn I, Mosialos G, "et al." |title=Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact "in vivo" with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation. |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=93 |issue= 24 |pages= 14053–8 |year= 1997 |pmid= 8943059 |doi=
*cite journal | author=Aizawa S, Nakano H, Ishida T, "et al." |title=Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation. |journal=J. Biol. Chem. |volume=272 |issue= 4 |pages= 2042–5 |year= 1997 |pmid= 8999898 |doi=
*cite journal | author=Lee SY, Lee SY, Choi Y |title=TRAF-interacting protein (TRIP): a novel component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits TRAF2-mediated NF-kappaB activation. |journal=J. Exp. Med. |volume=185 |issue= 7 |pages= 1275–85 |year= 1997 |pmid= 9104814 |doi=
*cite journal | author=Boucher LM, Marengère LE, Lu Y, "et al." |title=Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily. |journal=Biochem. Biophys. Res. Commun. |volume=233 |issue= 3 |pages= 592–600 |year= 1997 |pmid= 9168896 |doi= 10.1006/bbrc.1997.6509
*cite journal | author=Duckett CS, Thompson CB |title=CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival. |journal=Genes Dev. |volume=11 |issue= 21 |pages= 2810–21 |year= 1997 |pmid= 9353251 |doi=
*cite journal | author=Mizushima S, Fujita M, Ishida T, "et al." |title=Cloning and characterization of a cDNA encoding the human homolog of tumor necrosis factor receptor-associated factor 5 (TRAF5). |journal=Gene |volume=207 |issue= 2 |pages= 135–40 |year= 1998 |pmid= 9511754 |doi=
*cite journal | author=Kurts C, Carbone FR, Krummel MF, "et al." |title=Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. |journal=Nature |volume=398 |issue= 6725 |pages= 341–4 |year= 1999 |pmid= 10192335 |doi= 10.1038/18692

External links

*

PBB_Controls
update_page = yes
require_manual_inspection = no
update_protein_box = yes
update_summary = no
update_citations = yes